Divarasib vs Garsorasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Divarasib

Developed by Roche

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT06497556 · Phase 3 · active, not recruiting

The trial is randomized with a real active comparator (sotorasib or adagrasib) and a hard clinical endpoint (progression-free survival), and it reportedly met that endpoint with a statistically significant benefit. However, the study is open-label with no blinding of participants or investigators, which limits confidence in outcome assessment despite blinded independent central review of scans, so it falls short of the strongest tier of evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (Up to approximately 4 years): Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. (met)

Result source: NCT06497556

Garsorasib · Anfangning

Marketed by Sino Biopharmaceutical and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05383898 · Phase 1/2 · completed

The study was a non-randomized, open-label, single-arm trial with no placebo or active comparator, despite enrolling 225 participants. Its primary outcomes included safety measures and overall response rate. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT07472478 (registry estimate)

Reported efficacy

Subject incidence of Dose-limiting toxicities (DLT) (through out the DLT period, approximately 21 days); Number of subjects participants with adverse events (Through study completion, approximately 3 years); antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation (Through study completion, approximately 3 years): IRC-confirmed ORR 50% (61 of 123 patients; 95% CI 41-59) (not_applicable)

Result source: NCT05383898

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDivarasibGarsorasib
PFS, median—Trial running · NCT03178552—Trial running · NCT06300177
OS, median—Trial running · NCT03178552—Trial running · NCT06300177
ORR—Trial running · NCT03178552—Trial running · NCT06300177
Duration of response, median—Trial running · NCT03178552—Trial running · NCT06300177

PFS, median

Divarasib
—Trial running · NCT03178552
Garsorasib
—Trial running · NCT06300177

OS, median

Divarasib
—Trial running · NCT03178552
Garsorasib
—Trial running · NCT06300177

ORR

Divarasib
—Trial running · NCT03178552
Garsorasib
—Trial running · NCT06300177

Duration of response, median

Divarasib
—Trial running · NCT03178552
Garsorasib
—Trial running · NCT06300177
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Divarasib
Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. NCT06497556 · Phase 3 · design grade: moderate · publication or press release
Garsorasib
IRC-confirmed ORR 50% (61 of 123 patients; 95% CI 41-59) NCT05383898 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divarasib's landscape · Garsorasib's landscape